Preventing long-term tenofovir renal toxicity by pharmacokinetic assessment.
نویسندگان
چکیده
Tenofovir is the active metabolite of tenofovir disoproxil fumarate (TDF), a commonly used antiretroviral agent in HIV treatment and in HIV preexposure prophylaxis. After a long-term exposure, TDF is associated with kidney impairment. In the D:A:D study cohort of HIV-infected patients (22 603 HIV-infected patients with baseline estimated glomerular filtration rate (eGFR) 90 ml/min per 1.73 m), tenofovir exposure was associated after adjustment with an increased relative risk (1.18 a year) of developing chronic kidney disease (CKD) defined by the occurrence of an eGFR below 70 ml/min per 1.73 m [1]. Recent studies also suggested that tenofovir use in preexposure prophylaxis might also be associated with a weak decline in eGFR, a mean decrease in eGFR after 60 months of treatment was 6 ml/min in the Bangkok Tenofovir study [2], and around 2 ml/min per 1.73 m during a median follow-up of 18 months in Partners Prep Study [3]. The decline in eGFR associated with tenofovir use is not always reversible after treatment cessation [4]. Tenofovir has a mitochondrial toxicity in tubular cells, leading to kidney tubular dysfunction (KTD) [5]. KTD affects 10.6–19% of the patients receiving tenofovir [6,7]. Tubular tenofovir toxicity is probably dose dependent. Indeed, an association between high-trough tenofovir plasma concentrations and KTD (defined by hypophosphatemia, hypouricemia, nondiabetic glucosuria, b-2 microglobulinuria, or a-1 microglobulinuria) was previously observed [6,7]. However, a decrease in eGFR may be observed without evidence for KTD. It is crucial to identify mechanisms and risk factors of tenofovir renal toxicity. Tenofovir penetrates in tubular cells by several tubular transporters. Polymorphisms in genes encoding for tubular transporters organic cationic transporter 1, multidrug resistant protein 2 (MRP-2) and 4 (MRP-4) were associated with increased tenofovir plasma concentrations and increased risk of KTD or of decrease in eGFR [8–11].
منابع مشابه
Chronic Kidney Disease and Antiretroviral Therapy in HIV-Positive Individuals: Recent Developments.
Chronic kidney disease (CKD) has emerged as an important health concern in HIV-positive individuals. Preventing long-term kidney toxicity from an antiretroviral therapy is therefore critical. Selected antiretroviral agents, especially tenofovir disoproxil fumarate (TDF) and some ritonavir-boosted protease inhibitors (PI/rs), have been associated with increased risk of CKD. However, the CKD risk...
متن کاملLow Body Weight in Females Is a Risk Factor for Increased Tenofovir Exposure and Drug-Related Adverse Events
Treatment with tenofovir sometimes leads to non-reversible kidney and/or bone diseases. Factors associated with these drug-related adverse events are poorly characterized. Our objective was to investigate such factors in patients treated long term with daily tenofovir. One-hundred Caucasian HIV-positive patients with basal creatinine clearance >80 mL/min treated with tenofovir for at least 6 mo...
متن کاملThe role of drug transporters in the kidney: lessons from tenofovir
Tenofovir disoproxil fumarate, the prodrug of nucleotide reverse transcriptase inhibitor tenofovir, shows high efficacy and relatively low toxicity in HIV patients. However, long-term kidney toxicity is now acknowledged as a modest but significant risk for tenofovir-containing regimens, and continuous use of tenofovir in HIV therapy is currently under question by practitioners and researchers. ...
متن کاملRenal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial
BACKGROUND The prevalence of bipolar disorder in HIV-infected patients is higher than the general population. Lithium is the most effective mood stabiliser, while tenofovir disoproxil fumarate (TDF) is frequently used as part of combination antiretroviral therapy (ART). Both TDF and lithium are associated with renal tubular toxicity, which could be additive, or a pharmacokinetic interaction may...
متن کاملSide effects of long-term oral antiviral therapy for hepatitis B.
The aim of this review is to summarize the safety profile of the five approved oral nucleoside analogs used to treat chronic hepatitis B virus (HBV) infection, focusing on both the class adverse effects and those that have been reported with individual agents, as well as their safety in pregnancy. All nucleoside analogs have a "Black Box" warning because of their potential for inhibition of hum...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- AIDS
دوره 30 4 شماره
صفحات -
تاریخ انتشار 2016